Sten Fredrikson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6244001/publications.pdf

Version: 2024-02-01

158	6,480	61984	79698
papers	citations	43 h-index	73 g-index

164	164	164	6300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Multiple Sclerosis Journal, 2012, 18, 891-898.	3.0	654
2	Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. European Journal of Immunology, 1991, 21, 1461-1468.	2.9	246
3	Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 7113-7117.	7.1	241
4	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276.	10.1	181
5	Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. European Journal of Neurology, 2001, 8, 27-35.	3.3	155
6	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1116-1121.	1.9	139
7	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens, 2004, 63, 237-247.	1.0	130
8	Selective Decline in Information Processing in Subgroups of Multiple Sclerosis: An 8-Year Longitudinal Study. European Neurology, 2007, 57, 193-202.	1.4	119
9	Radiologically isolated syndrome â€“ incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Multiple Sclerosis Journal, 2013, 19, 271-280.	3.0	116
10	Interleukin-6 is elevated in plasma in multiple sclerosis. Journal of Neuroimmunology, 1991, 31, 147-153.	2.3	114
11	Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurologica Scandinavica, 1994, 90, 160-166.	2.1	111
12	Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study. American Journal of Neuroradiology, 2016, 37, 1023-1029.	2.4	104
13	Î³Î´+ T cells are increased in patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 121, 39-45.	0.6	103
14	Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurologica Scandinavica, 1997, 95, 280-283.	2.1	101
15	Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. Journal of Neuroimmunology, 1999, 99, 82-90.	2.3	91
16	Elevated Suicide Risk among Patients with Multiple Sclerosis in Sweden. Neuroepidemiology, 2003, 22, 146-152.	2.3	91
17	Activities of daily living and social activities in people with multiple sclerosis in Stockholm County. Clinical Rehabilitation, 2006, 20, 543-551.	2.2	88
18	Multiple sclerosis:. Journal of Neuroimmunology, 2000, 108, 236-243.	2.3	83

#	Article	IF	Citations
19	Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. Journal of Neuroimmunology, 1996, 64, 63-69.	2.3	80
20	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes and Immunity, 2002, 3, 279-285.	4.1	73
21	Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. Journal of Neuroimmunology, 1992, 38, 63-73.	2.3	72
22	Multiple Sclerosis: Levels of Interleukin-10-Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon-beta-1b Treatment. Scandinavian Journal of Immunology, 1999, 49, 554-561.	2.7	67
23	Neutralizing and binding anti-interferon-Î² (IFN-Î²) antibodies. A comparison between IFN-Î²-1a and IFN-Î²-1b treatment in multiple sclerosis. European Journal of Neurology, 2000, 7, 27-34.	3.3	67
24	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	3.0	66
25	Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain, 1998, 78, 153-155.	4.2	65
26	Increased mRNA Expression of IL-10 in Mononuclear Cells in Multiple Sclerosis and Optic Neuritis. Scandinavian Journal of Immunology, 1995, 41, 171-178.	2.7	64
27	Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. Journal of Neuroimmunology, 1998, 86, 13-19.	2.3	63
28	Costs and quality of life of multiple sclerosis in Sweden. European Journal of Health Economics, 2006, 7, 75-85.	2.8	63
29	Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study. Multiple Sclerosis Journal, 2015, 21, 1151-1158.	3.0	63
30	IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clinical and Experimental Immunology, 1998, 111, 193-197.	2.6	60
31	Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Multiple Sclerosis Journal, 2006, 12, 605-612.	3.0	58
32	CSF immune variables in patients with narcolepsy. Acta Neurologica Scandinavica, 2009, 81, 253-254.	2.1	57
33	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs, 2017, 31, 33-50.	5.9	57
34	Similar Humoral and Cellular Immunological Reactivities to Human Herpesvirus 6 in Patients with Multiple Sclerosis and Controls. Vaccine Journal, 1999, 6, 545-549.	2.6	57
35	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 448-454.	3.0	55
36	Organ-specific autoantigens induce transforming growth factor-Î² mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Annals of Neurology, 1994, 35, 197-203.	5.3	54

#	Article	IF	Citations
37	Multiple sclerosis: the proinflammatory cytokines lymphotoxin-Î± and tumour necrosis factor-Î± are upregulated in cerebrospinal fluid mononuclear cells. Journal of Neuroimmunology, 1996, 66, 115-123.	2.3	52
38	Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Annals of Neurology, 1999, 46, 612-616.	5.3	52
39	Cognitive and motor function in people with multiple sclerosis in Stockholm County. Multiple Sclerosis Journal, 2006, 12, 340-353.	3.0	52
40	Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. American Journal of Neuroradiology, 2017, 38, 1311-1316.	2.4	48
41	Tumor necrosis factor-Î±, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 191-198.	2.3	47
42	Interferon Â for secondary progressive multiple sclerosis: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 420-426.	1.9	47
43	Transforming growth factor-Î²1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. Journal of Neuroimmunology, 1995, 58, 21-35.	2.3	46
44	CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurologica Scandinavica, 1987, 75, 352-355.	2.1	45
45	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268.	4.1	44
46	Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health and Quality of Life Outcomes, 2010, 8, 133.	2.4	44
47	The HLA-Dw2 haplotype segregates closely with multiple sclerosis in multiplex families. Journal of Neuroimmunology, 1994, 50, 95-100.	2.3	43
48	Clinical epidemiology of Guillainâ€“BarrÃ© syndrome in adults in Sweden 1996â€“97: a prospective study. European Journal of Neurology, 2000, 7, 685-692.	3.3	43
49	Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Annals of Neurology, 2020, 87, 710-724.	5.3	42
50	T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis. Scandinavian Journal of Immunology, 1993, 37, 355-368.	2.7	41
51	Distinct pattern of age-specific incidence of Guillain-BarrÃ© syndrome in Harbin, China. Journal of Neurology, 2002, 249, 25-32.	3.6	41
52	Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 375-380.	1.9	41
53	Guillain-BarrÃ© syndrome in South-West Stockholm, 1973-1991, 1. Quality of registered hospital diagnoses and incidence. Acta Neurologica Scandinavica, 1995, 91, 109-117.	2.1	41
54	Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study. Multiple Sclerosis Journal, 2008, 14, 962-971.	3.0	40

#	Article	IF	Citations
55	A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality. Journal of the Neurological Sciences, 2013, 332, 121-127.	0.6	40
56	MRIâ€Defined Corpus Callosal Atrophy in Multiple Sclerosis: A Comparison of Volumetric Measurements, Corpus Callosum Area and Index. Journal of Neuroimaging, 2015, 25, 996-1001.	2.0	40
57	Incidence of Radiologically Isolated Syndrome: A Population-Based Study. American Journal of Neuroradiology, 2016, 37, 1017-1022.	2.4	40
58	Cost-utility of interferon Î² 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. European Journal of Health Economics, 2003, 4, 50-59.	2.8	39
59	Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurologica Scandinavica, 1996, 94, 31-34.	2.1	37
60	Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-Î²and IL-10. Clinical and Experimental Immunology, 2002, 124, 306-314.	2.6	37
61	Cells producing antibodies specific for myelin basic protein region 70â€“89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. European Journal of Immunology, 1991, 21, 2971-2976.	2.9	36
62	Augmented interferon-Î³, interleukin-4 and transforming growth factor-Î² mRNA expression in blood mononuclear cells in myasthenia gravis. Journal of Neuroimmunology, 1994, 51, 185-192.	2.3	36
63	COST-UTILITY ANALYSIS OF INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS. International Journal of Technology Assessment in Health Care, 2000, 16, 768-780.	0.5	35
64	CNS-borreliosis selectively affecting central motor neurons. Acta Neurologica Scandinavica, 1988, 78, 181-184.	2.1	34
65	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology, 2017, 24, 516-522.	3.3	34
66	Interleukinâ€12 and Perforin mRNA Expression is Augmented in Blood Mononuclear Cells in Multiple Sclerosis. Scandinavian Journal of Immunology, 1998, 47, 582-590.	2.7	32
67	Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. Journal of Neurology, 1989, 236, 238-242.	3.6	31
68	CD5+ B cells and CD4â^'8â^' T cells in neuroimmunological diseases. Journal of Neuroimmunology, 1991, 32, 123-132.	2.3	31
69	Multiple sclerosis in Stockholm County. A pilot study exploring the feasibility of assessment of impairment, disability and handicap by home visits. Clinical Rehabilitation, 2003, 17, 294-303.	2.2	30
70	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. Genes and Immunity, 2000, 1, 456-459.	4.1	29
71	T cell responses to human recombinant acetylcholine receptor-Î± subunitin myasthenia gravis and controls. European Journal of Immunology, 1992, 22, 1553-1559.	2.9	28
72	Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Multiple Sclerosis Journal, 2008, 14, 671-678.	3.0	28

#	Article	IF	Citations
73	A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images. Neuroradiology, 2010, 52, 109-117.	2.2	28
74	Callosal atrophy in multiple sclerosis is related to cognitive speed. Acta Neurologica Scandinavica, 2013, 127, 281-289.	2.1	28
75	Lyme Neuroborreliosis: Evidence for Persistent Up-Regulation of Borrelia Burgdorferi-Reactive Cells Secreting Interferon-gamma. Scandinavian Journal of Immunology, 1995, 42, 694-700.	2.7	27
76	Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurologica Scandinavica, 2012, 125, 129-135.	2.1	27
77	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis Journal, 2004, 10, 5-8.	3.0	24
78	"We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran. Health Research Policy and Systems, 2010, 8, 9.	2.8	24
79	A 10-year follow-up of the European multicenter trial of interferon Î²-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 533-543.	3.0	24
80	Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. American Journal of Neuroradiology, 2019, 40, 1265-1273.	2.4	24
81	Interleukin-2 secreting cells in multiple sclerosis and controls. Journal of the Neurological Sciences, 1993, 120, 99-106.	0.6	23
82	No eidence for increased frequency of autoantibodies during interferon-Î²_{Ib}treatment of multiple sclerosis. Acta Neurologica Scandinavica, 1998, 97, 320-323.	2.1	23
83	Association and linkage analysis of candidate chromosomal regions in multiple sclerosis: indication of disease genes in 12q23 and 7ptrâ€“15. European Journal of Human Genetics, 1999, 7, 110-116.	2.8	23
84	Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: A comparison of descriptive characteristics. Scandinavian Journal of Public Health, 2013, 41, 492-499.	2.3	23
85	Increased reactivity to HTLV-I in inflammatory nervous system diseases. Annals of Neurology, 1987, 22, 67-71.	5.3	22
86	Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals. Journal of Neuroimmunology, 1995, 56, 99-105.	2.3	22
87	Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. European Journal of Neurology, 1998, 5, 265-275.	3.3	21
88	Diffusion of magnetic resonance imaging in Iran. International Journal of Technology Assessment in Health Care, 2007, 23, 278-285.	0.5	21
89	Multiple sclerosis in Pakistan. Multiple Sclerosis Journal, 2007, 13, 668-669.	3.0	21
90	Is excessive daytime sleepiness a separate manifestation in Parkinson's disease?. Acta Neurologica Scandinavica, 2015, 132, 97-104.	2.1	20

#	Article	IF	Citations
91	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	2.8	20
92	Lesion accumulation is predictive of long-term cognitive decline in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 21, 110-116.	2.0	20
93	The T-Cell Repertoire in Myasthenia Gravis Involves Multiple Cholinergic Receptor Epitopes. Scandinavian Journal of Immunology, 1992, 36, 405-414.	2.7	19
94	Expression of IFN-Î³, IL-4, and TGF-Î² in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Multiple Sclerosis Journal, 1995, 1, 173-180.	3.0	19
95	HHV-6 A- or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum. Journal of Medical Virology, 2002, 66, 394-399.	5.0	19
96	The first case history of multiple sclerosis: Augustus dâ€™EstÃ© (1794â€“1848). Neurological Sciences, 2010, 31, 29-33.	1.9	19
97	Combination ELISAs for antiviral antibodies in CSF and serum in patients with neurological symptoms and in healthy controls. Journal of Virological Methods, 1988, 19, 169-179.	2.1	18
98	The 150-Year Anniversary of Multiple Sclerosis: Does Its Early History Give an Etiological Clue?. Perspectives in Biology and Medicine, 1989, 32, 237-243.	0.5	18
99	Myasthenia gravis: T and B cell reactivities to the Î²-bungarotoxin binding protein presynaptic membrane receptor. Journal of the Neurological Sciences, 1992, 109, 173-181.	0.6	18
100	No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. Journal of Neuroimmunology, 1998, 91, 108-112.	2.3	18
101	Detection of Leukocortical Lesions in Multiple Sclerosis and Their Association with Physical and Cognitive Impairment: A Comparison of Conventional and Synthetic Phase-Sensitive Inversion Recovery MRI. American Journal of Neuroradiology, 2018, 39, 1995-2000.	2.4	17
102	Multiple sclerosis in Stockholm County. A pilot study of utilization of health-care resources, patient satisfaction with care and impact on family caregivers. Acta Neurologica Scandinavica, 2002, 106, 241-247.	2.1	16
103	Epidemiological surveillance ofGuillain-BarrÃ© syndrome in Sweden,1996-1997. Acta Neurologica Scandinavica, 2000, 101, 104-111.	2.1	15
104	Effects of inpatient rehabilitation in multiple sclerosis patients with moderate disability. Advances in Physiotherapy, 2008, 10, 58-65.	0.2	15
105	Prospective study of clinical epidemiology of Guillainâ€“BarrÃ© syndrome in Harbin, China. Journal of the Neurological Sciences, 2003, 215, 63-69.	0.6	14
106	HLA CLASS II GENES IN CHRONIC PROGRESSIVE AND IN RELAPSING/REMITTING MULTIPLE SCLEROSIS. Lancet, The, 1987, 330, 327.	13.7	13
107	Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 1999, 24, 1033-1035.	2.4	13
108	How is magnetic resonance imaging used in Iran?. International Journal of Technology Assessment in Health Care, 2008, 24, 452-458.	0.5	13

#	Article	IF	Citations
109	Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis. Clinical Therapeutics, 2012, 34, 1132-1144.	2.5	13
110	Radiologically isolated syndrome: an uncommon finding at a university clinic in a high-prevalence region for multiple sclerosis. BMJ Open, 2013, 3, e003531.	1.9	13
111	Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. Acta Neurologica Scandinavica, 1994, 90, 10-18.	2.1	12
112	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology, 2018, 25, 739-746.	3.3	12
113	A New Cell Enzyme-Linked Immunosorbent Assay Demonstrates Gamma Interferon Suppression by Beta Interferon in Multiple Sclerosis. Vaccine Journal, 1999, 6, 415-419.	2.6	12
114	High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions. Acta Neurologica Scandinavica, 1999, 100, 18-24.	2.1	11
115	Lessons from randomised direct comparative trials. Journal of the Neurological Sciences, 2009, 277, S19-S24.	0.6	11
116	RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif. PLoS ONE, 2019, 14, e0218453.	2.5	11
117	Decreased mRNA expression of TNF-alpha and IL-10 in non-stimulated peripheral blood mononuclear cells in myasthenia gravis. European Journal of Neurology, 2000, 7, 195-202.	3.3	10
118	Genomic HLAâ€typing by RFLPâ€analysis using DRÎ² and DQÎ² cDNA probes reveals normal DRâ€DQ linkages in patients with multiple sclerosis. Tissue Antigens, 1987, 30, 135-138.	1.0	10
119	Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members. Acta Neurologica Scandinavica, 1994, 89, 184-189.	2.1	10
120	A 10-Year Follow-Up of Excessive Daytime Sleepiness in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-7.	1.1	10
121	VÎ´1 gene usage, interleukin-2 receptors and adhesion molecules on Î³Î´+ T cells in inflammatory disease of the nervous system. Journal of Neuroimmunology, 1994, 49, 59-66.	2.3	9
122	Evaluation of multiple sclerosis diagnostic criteria in Suzhou, China Ã¢Â€Â“ risk of under-diagnosis in a low prevalence area. Acta Neurologica Scandinavica, 2010, 121, 24-29.	2.1	9
123	Mononuclear Cell Types in Cerebrospinal Fluid and Blood of Patients With Multiple Sclerosis. Archives of Neurology, 1989, 46, 372.	4.5	8
124	Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiology and Drug Safety, 2008, 17, 934-941.	1.9	8
125	Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsingâ€“remitting multiple sclerosis in Sweden. Journal of Medical Economics, 2013, 16, 349-357.	2.1	8
126	Multiple sclerosis in Pakistan: Current status and future perspective. Journal of the Neurological Sciences, 2020, 418, 117066.	0.6	8

#	Article	IF	Citations
127	A caseâ€“control study of Guillainâ€“Barre syndrome in Harbin, China. European Journal of Neurology, 2006, 13, 953-957.	3.3	7
128	Cord blood contains cells secreting antibodies to nervous system components. Clinical and Experimental Immunology, 2008, 84, 353-358.	2.6	7
129	A single-group pilot feasibility study of cognitive behavioural therapy in people with multiple sclerosis with depressive symptoms. Disability and Rehabilitation, 2016, 38, 2383-2391.	1.8	7
130	Associations Between Fluctuations in Daytime Sleepiness and Motor and Nonâ€Motor Symptoms in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 44-50.	1.5	7
131	Guillain-BarrÃ© syndrome in South-West Stockholm, 1973â€“1991, 2. Clinical epidemiology. Italian Journal of Neurological Sciences, 1997, 18, 49-53.	0.1	6
132	Interferon-Î² treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. British Journal of Clinical Pharmacology, 2003, 56, 337-340.	2.4	6
133	The expression of TNF-Î± receptors 1 and 2 on peripheral blood mononuclear cells in chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2008, 200, 129-132.	2.3	6
134	Telephone validation of an Urdu translated version of the extended disability severity scale in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 48, 102684.	2.0	6
135	First hospital-admission rate as an epidemidogical indicator for patients with multiple sclerosis in Stockholm, 1984-1993. Acta Neurologica Scandinavica, 1999, 100, 64-68.	2.1	5
136	Reports of Patients and Relatives from the CogniCIS Study about Cognition in Clinically Isolated Syndrome: What Are Our Patients Telling Us?. European Neurology, 2013, 69, 346-351.	1.4	5
137	A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. Journal of Medical Economics, 2013, 16, 756-762.	2.1	5
138	Multiple sclerosis in Pakistan: histocompatibility antigen composition and disability. Multiple Sclerosis Journal, 2013, 19, 254-255.	3.0	5
139	Health-related quality of life in partners of persons with MS: a longitudinal 10-year perspective. BMJ Open, 2014, 4, e006097.	1.9	5
140	Multiple sclerosis among firstâ€•and secondâ€generation immigrant groups in Sweden. Acta Neurologica Scandinavica, 2020, 142, 339-349.	2.1	5
141	Retrovirus in multiple sclerosis. Acta Neurologica Scandinavica, 1989, 80, 467-471.	2.1	4
142	Bone marrow cells in patients with multiple sclerosis. Journal of Neuroimmunology, 1989, 24, 23-31.	2.3	4
143	A zone immunoelectrophoresis assay method for quantification of apolipoprotein D in human cerebrospinal fluid. Journal of Proteomics, 1996, 33, 1-8.	2.4	4
144	Lyme neuroborreliosis: cerebrospinal fluid contains myelin proteinâ€•reactive cells secreting interferonâ€Î³. European Journal of Neurology, 1996, 3, 122-129.	3.3	4

#	Article	IF	Citations
145	Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other nervous system diseases. Acta Neurologica Scandinavica, 1997, 95, 99-102.	2.1	4
146	Multiple sclerosis and amyloid deposits in the white matter of the brain. Acta Neuropathologica, 1997, 93, 205-209.	7.7	4
147	The B-cell repertoire in myasthenia gravis includes all four acetylcholine receptor subunits. Acta Neurologica Scandinavica, 1998, 98, 422-426.	2.1	4
148	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14â€“13. Genes and Immunity, 2001, 2, 451-454.	4.1	4
149	People with multiple sclerosis in Denmark who use complementary and alternative medicineâ€”Do subgroups of patients differ?. European Journal of Integrative Medicine, 2013, 5, 365-373.	1.7	4
150	Parkinsonâ€™s Disease Among Immigrant Groups and Swedish-Born Individuals: A Cohort Study of All Adults 50 Years of Age and Older in Sweden. Journal of Parkinson's Disease, 2020, 10, 1133-1141.	2.8	4
151	Bone Marrow Cells in Multiple Sclerosis.. Annals of the New York Academy of Sciences, 1988, 540, 282-285.	3.8	3
152	Picornavirus May Be Linked to Parkinsonâ€™s Disease through Viral Antigen in Dopamine-Containing Neurons of Substantia Nigra. Microorganisms, 2022, 10, 599.	3.6	2
153	Narcolepsy among firstâ€•and secondâ€generation immigrants in Sweden: A study of the total population. Acta Neurologica Scandinavica, 2022, 146, 160-166.	2.1	2
154	Epilepsy in immigrants and Swedish-born: A cohort study of all adults 18 years of age and older in Sweden. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 116-122.	2.0	1
155	Huntingtonâ€™s disease among immigrant groups and Swedish-born individuals: a cohort study of all adults 18 years of age and older in Sweden. Neurological Sciences, 2021, 42, 3851-3856.	1.9	1
156	Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Annals of Neurology, 1999, 46, 612-616.	5.3	1
157	Emerging Oral Medications for Multiple Sclerosis. , 2012, , .		0
158	Amyotrophic lateral sclerosis (ALS) among immigrant groups and Swedish-born individuals: a cohort study of all adults 18Âyears of age and older in Sweden. Journal of Neurology, 2021, , 1.	3.6	0